Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds

Advertising today archive

3194 PWToday Stories

IXALTIS stengthens its portfolio by entering into an agreement witn XIGEN

03 Oct 17

Ixaltis, the start-up specialized in developing treatments for urogenital disorders, and Xigen, a privately-owned biopharmaceutical company that specializes in the development of peptides for use against inflammation, have signed an option agreement for exclusive worldwide rights to one compound in urogenital diseases.
Following this agreement, Ixaltis will perform preclinical proof of concept (POC) for two of Xigen’s compounds - XG-102 and XG-104 - in animal models and human tissues. XG-102, an innovative JNK inhibitor, has been successfully tested in clinical trials for ocular diseases and is already licensed out for another promising indication. XG-104, a second JNK inhibitor, is an L/D-amino-acids peptide.
In the case of positive outcome in the POC program, the selected compound, either XG-102 or XG-104, would be expected to enter a phase 1/2 clinical trial in patients to demonstrate safety and efficacy in a urogenital indication with high unmet medical need such as Interstitial cystitis.
“This agreement, said Roberto Gradnik, CEO of Ixaltis, represents a significant step forward for us in the path to become a leading developer of innovative treatments for urogenital diseases”.
Having already acquired the rights for Litoxetine IXA-001, the agreement with Xigen allows Ixaltis to extend its portfolio of innovative compounds used for urinary disorders with a very high unmet medical need.

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.